Navigation Links
Auxilium Pharmaceuticals, Inc. To Present At The Oppenheimer Conference
Date:12/5/2013

CHESTERBROOK, Pa., Dec. 5, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that executive management will participate in the Oppenheimer 24th Annual Conference to be held December 10-11, 2013 at the Crown Plaza in New York. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 9:30 a.m. ET on Wednesday, December 11, 2013.  

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

The presentation will also be webcast on the "For Investors" section of the Auxilium website under the "Events" tab. To access the live webcast, please log on to Auxilium's website approximately 15 minutes prior to the presentation to register and download any necessary audio software. The presentation replay will be available for 90 days after the event.About Auxilium Auxilium Pharmaceuticals, Inc. is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing products to predominantly specialist audiences. Auxilium markets Testim (testosterone gel) for the topical treatment of hypogonadism in the U.S. and XIAFLEX for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada. Swedish Orphan Biovitrium AB has marketing rights for XIAPEX (the EU tradename for CCH) in 71 Eurasian and African countries. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan and Actelion Pharmaceuticals Ltd has development and commercial rights for
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
2. Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
3. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
4. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
5. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
6. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
7. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals to Announce Third Quarter 2012 Results and Conduct Conference Call on Wednesday, November 7, 2012
9. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
11. Auxilium Pharmaceuticals, Inc. Announces Pricing of $325.0 Million of 1.50% Convertible Senior Notes Due 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" ... developing and commercializing proven cancer therapies in new ... from its Phase I/II clinical trial of  VAL-083 ... the most common and deadly form of human ...
(Date:6/1/2015)... , June 1, 2015 CEFALY ... electrical nerve stimulation device specifically authorized for use prior ... data from a new PET trial showing that the ... in the brain in migraine patients, namely the orbitofrontal ... Tomography (PET) scan, which is an imaging test of the brain, used ...
(Date:6/1/2015)... June 1, 2015  Boston Biomedical, an industry leader ... cancer stem cell (CSC) pathways, will present clinical data ... multiple tumor types at the 2015 American Society of ... . Data presented at ASCO highlight ... that targets STAT3, leading to inhibition of the critical ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Linda Cade as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... recognize Linda with this important honor,” said NAPW President ...
(Date:6/1/2015)... 02, 2015 The National Association ... Cornett, DSL, LSSBB (C), First Sergeant A Co., 15BSB ... of the Year Circle. She is recognized with this ... the nation's leading networking organization exclusively for professional women, ... Local Chapters. , “I'm pleased to recognize Sergeant Cornett ...
(Date:6/1/2015)... Ticket Down announces that the Golden State Warriors ... and now will face the Cleveland Cavaliers in the ... Oracle Arena in Oakland and the Quicken Loans Arena in ... season, the Golden State Warriors were the elite team that ... from their playoff failures from the year and riding the ...
(Date:6/1/2015)... CO (PRWEB) June 01, 2015 Atagi ... they have been named an Ultherapy® Ultra ... Plastic Surgery and Skin Aesthetics is one of only ... as a premier treatment provider. , Atagi Plastic ... in the Denver area has led the practice to ...
(Date:6/1/2015)... 2015 Rio Salado College’s Dental Clinic ... young adults this summer. , The clinics take place Friday, ... 3 p.m. at the Rio Salado Dental Clinic. The clinic ... “A big goal for us is to offer services to ... students,” said Nikki Shipp, Clinical Coordinator for Rio’s dental hygiene. ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:Kids Receive Complimentary Dental Services at Rio Salado Dental Clinic 2
... Dental Laser Market, SAN CLEMENTE, Calif., Feb. ... Inc. (Nasdaq: BLTI ) announced the,formation of ... laser,division, Lasers4Dentistry, and a laser therapy division,Technology4Therapy. Jeffrey ... and Keith G. Bateman, Biolase,s former Executive Vice ...
... Va., Feb. 21 Federal Health Information,Technology (IT) spending ... $4.5,billion in 2013 at a compound annual growth rate ... IT market, according to a new report by,INPUT, the ... robust, several things remain in the way of even,more ...
... and Water Reuse are Honored, NEW ... curricular solution for pharmacy education, has been,awarded ... Electronic Publication or,Product from the Professional/Scholarly Publishing ... In addition, the McGraw-Hill,reference, Water Reuse: Issues, ...
... release is available in Spanish . , ... Country, Maria Luisa de Francisco Maiz provided a clinical-forensic evaluation ... that influence the length of legal time periods. , Brain ... only for their high incidence but also because they mainly ...
... There are numerous antidepressant medications currently on ... the debilitating symptoms of depression even with treatment. ... 15th issue of Biological Psychiatry set out to ... serotonin and norepinephrine reuptake inhibitors (SNRIs), like venlafaxine ...
... . , Ikerlan-IK4 (CIC microGUNE Microfluidics Unit - ... device that enables the verification of the optimum conditions for ... a microelectrode that measures the impedance and temperature of the ... be monitored from the moment of its extraction, during its ...
Cached Medicine News:Health News:Former Biolase CEO & EVP Launch Technology4Medicine 2Health News:Federal Health IT Market to Reach $4.5 Billion by 2013 2Health News:McGraw-Hill Professional Products Win Awards From Association of American Publishers 2Health News:Guidelines for evaluation of psychological side-effects of brain injury 2Health News:Guidelines for evaluation of psychological side-effects of brain injury 3Health News:Comparison of venlafaxine and SSRIs in the treatment of depression 2Health News:A device that measures optimum state of an organ prior to transplanting has been patented 2
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... is a latex-free unisex system that ... catheterization designed to reduce the risk ... includes a 100% latex-free Mentor Self-Cath ... tab makes it easy to use, ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: